Oncologist in Guatemala
Your diagnosis has a name. So does your treatment.
Medical oncologist specializing in solid tumors, with 8+ years treating lung, breast, colon, prostate, and other cancers in Guatemala City.
Dr. Giovanni José Manuel Reynoso Lemus
Specialist in Medical Oncology and Solid Tumors
8+ years of experience | Member of ASCO and ESMO | License #14622
Training built across three countries.
“Receiving a cancer diagnosis changes everything in an instant. What comes next — the plan, the treatment, the decisions — depends on having someone who understands the biology of the tumor, but also the context of the person living with it. That’s what I try to do in every consultation.”Dr. Giovanni Reynoso
Years of experience in Medical Oncology and solid tumors
Countries of training — Guatemala, Mexico, and Spain
Member of the world’s two most influential oncology societies
Per consultation — real time to understand your case
Oncology treatment
specific to your tumor type
Medical oncology consultations in Guatemala City, with molecular diagnostics, up-to-date protocols, and a treatment plan designed around each tumor’s biology.
Breast Cancer
HER2+ · Luminal · Triple negative
Systemic treatment based on molecular subtype — luminal, HER2-positive, and triple negative. Chemotherapy, anti-HER2 therapy, endocrine therapies, and immunotherapy in coordination with surgery and radiotherapy.
Key benefits:
- Treatment tailored to full molecular subtype
- Management of early, locally advanced, and metastatic disease
- Anti-HER2 and endocrine therapies available
- Multidisciplinary coordination with surgery and radiotherapy
Lung Cancer
Non-small cell · Small cell · Molecular
Non-small cell and small cell lung cancer with complete molecular testing — EGFR, ALK, ROS1, BRAF, MET, and PD-L1. Targeted therapies and immunotherapy based on molecular profile.
Key benefits:
- Complete molecular testing to identify targeted therapies
- Immunotherapy based on PD-L1 expression
- Management of localized, locally advanced, and metastatic disease
- Targeted therapies for EGFR, ALK, ROS1, and other mutations
Colon and Rectal Cancer
Localized · Metastatic · MSI
Colorectal cancer at all stages, with MSI/MMR testing and RAS/BRAF mutation analysis. Chemotherapy, anti-VEGF and anti-EGFR antibodies, and immunotherapy for MSI-high tumors.
Key benefits:
- MSI/MMR testing and RAS/BRAF mutation analysis from diagnosis
- Immunotherapy available for MSI-high tumors
- Management of metastatic disease with curative intent when applicable
- Coordination with surgery and radiotherapy for localized disease
Prostate Cancer
Hormone-sensitive · Castration-resistant
Hormone-sensitive and castration-resistant prostate cancer, including metastatic disease. Next-generation endocrine therapies, chemotherapy, and PARP inhibitors for BRCA mutations.
Key benefits:
- Management of all disease stages
- Next-generation endocrine therapies (enzalutamide, abiraterone, darolutamide)
- PARP inhibitors for tumors with BRCA mutations
- Coordination with urology and radiotherapy
Gastric Cancer
Esophageal · Gastroesophageal junction · Stomach
Gastric and gastroesophageal junction adenocarcinoma with HER2, PD-L1, and MSI testing. Perioperative chemotherapy, anti-HER2 therapy, and immunotherapy. Specific training in digestive tumors — UAM Madrid.
Key benefits:
- Specific training in digestive tumors — UAM Madrid
- HER2, PD-L1, and MSI testing from diagnosis
- Immunotherapy with pembrolizumab available for select cases
- Perioperative management in coordination with surgery
Head and Neck Tumors
Squamous cell carcinoma · HPV · Recurrent
Squamous cell carcinomas of the head and neck — oral cavity, oropharynx, larynx, hypopharynx, and nasopharynx. Cisplatin as a radiosensitizer, cetuximab, and immunotherapy for recurrent or metastatic disease.
Key benefits:
- Management of locally advanced and recurrent disease
- Immunotherapy available for metastatic disease
- Coordination with head and neck surgery and radiotherapy
- Management of toxicities from cisplatin treatment
Melanoma and Advanced Skin Cancer
Metastatic melanoma · BRAF · Immunotherapy
Advanced and metastatic melanoma with BRAF mutation testing. Targeted therapy with dabrafenib and trametinib for BRAF-mutated tumors. First-line anti-PD1 and anti-CTLA4 immunotherapy. Merkel cell carcinoma and other skin tumors.
Key benefits:
- BRAF mutation testing to identify targeted therapy
- Anti-PD1 immunotherapy available as first-line treatment
- Management of immune-related toxicities
- Coordination with dermatology and surgical oncology
Other Solid Tumors
Kidney · Pancreas · Liver · Sarcomas · More
Kidney, bladder, pancreatic, liver, endometrial, ovarian, neuroendocrine tumors, sarcomas, advanced thyroid, and cervical cancer. Same approach: molecular diagnosis, ASCO and ESMO guidelines, and real time to understand each case.
Key benefits:
- ASCO and ESMO guidelines for all types of solid tumors
- Identification of molecular markers not yet tested
- Second opinions for rare tumors in Guatemala
- A full hour to review the case regardless of diagnosis
Oncology Second Opinion
Independent review · Complex cases · Failed treatment
Independent review of the oncologic diagnosis, staging, and proposed treatment plan. Recommended before starting treatment, when progressing on current therapy, or to confirm that the proposed protocol is correct for that tumor type and stage.
Key benefits:
- Independent review with no obligation to the prior diagnosis
- Analysis of molecular profile and markers if not yet performed
- Evaluation of available treatment alternatives
- In coordination with your treating physician — not against them
Breast Cancer
HER2+ · Luminal · Triple negative
Systemic treatment based on molecular subtype — luminal, HER2-positive, and triple negative. Chemotherapy, anti-HER2 therapy, endocrine therapies, and immunotherapy in coordination with surgery and radiotherapy.
Key benefits:
- Treatment tailored to full molecular subtype
- Management of early, locally advanced, and metastatic disease
- Anti-HER2 and endocrine therapies available
- Multidisciplinary coordination with surgery and radiotherapy
Lung Cancer
Non-small cell · Small cell · Molecular
Non-small cell and small cell lung cancer with complete molecular testing — EGFR, ALK, ROS1, BRAF, MET, and PD-L1. Targeted therapies and immunotherapy based on molecular profile.
Key benefits:
- Complete molecular testing to identify targeted therapies
- Immunotherapy based on PD-L1 expression
- Management of localized, locally advanced, and metastatic disease
- Targeted therapies for EGFR, ALK, ROS1, and other mutations
Colon and Rectal Cancer
Localized · Metastatic · MSI
Colorectal cancer at all stages, with MSI/MMR testing and RAS/BRAF mutation analysis. Chemotherapy, anti-VEGF and anti-EGFR antibodies, and immunotherapy for MSI-high tumors.
Key benefits:
- MSI/MMR testing and RAS/BRAF mutation analysis from diagnosis
- Immunotherapy available for MSI-high tumors
- Management of metastatic disease with curative intent when applicable
- Coordination with surgery and radiotherapy for localized disease
Prostate Cancer
Hormone-sensitive · Castration-resistant
Hormone-sensitive and castration-resistant prostate cancer, including metastatic disease. Next-generation endocrine therapies, chemotherapy, and PARP inhibitors for BRCA mutations.
Key benefits:
- Management of all disease stages
- Next-generation endocrine therapies (enzalutamide, abiraterone, darolutamide)
- PARP inhibitors for tumors with BRCA mutations
- Coordination with urology and radiotherapy
Gastric Cancer
Esophageal · Gastroesophageal junction · Stomach
Gastric and gastroesophageal junction adenocarcinoma with HER2, PD-L1, and MSI testing. Perioperative chemotherapy, anti-HER2 therapy, and immunotherapy. Specific training in digestive tumors — UAM Madrid.
Key benefits:
- Specific training in digestive tumors — UAM Madrid
- HER2, PD-L1, and MSI testing from diagnosis
- Immunotherapy with pembrolizumab available for select cases
- Perioperative management in coordination with surgery
Head and Neck Tumors
Squamous cell carcinoma · HPV · Recurrent
Squamous cell carcinomas of the head and neck — oral cavity, oropharynx, larynx, hypopharynx, and nasopharynx. Cisplatin as a radiosensitizer, cetuximab, and immunotherapy for recurrent or metastatic disease.
Key benefits:
- Management of locally advanced and recurrent disease
- Immunotherapy available for metastatic disease
- Coordination with head and neck surgery and radiotherapy
- Management of toxicities from cisplatin treatment
Melanoma and Advanced Skin Cancer
Metastatic melanoma · BRAF · Immunotherapy
Advanced and metastatic melanoma with BRAF mutation testing. Targeted therapy with dabrafenib and trametinib for BRAF-mutated tumors. First-line anti-PD1 and anti-CTLA4 immunotherapy. Merkel cell carcinoma and other skin tumors.
Key benefits:
- BRAF mutation testing to identify targeted therapy
- Anti-PD1 immunotherapy available as first-line treatment
- Management of immune-related toxicities
- Coordination with dermatology and surgical oncology
Other Solid Tumors
Kidney · Pancreas · Liver · Sarcomas · More
Kidney, bladder, pancreatic, liver, endometrial, ovarian, neuroendocrine tumors, sarcomas, advanced thyroid, and cervical cancer. Same approach: molecular diagnosis, ASCO and ESMO guidelines, and real time to understand each case.
Key benefits:
- ASCO and ESMO guidelines for all types of solid tumors
- Identification of molecular markers not yet tested
- Second opinions for rare tumors in Guatemala
- A full hour to review the case regardless of diagnosis
Oncology Second Opinion
Independent review · Complex cases · Failed treatment
Independent review of the oncologic diagnosis, staging, and proposed treatment plan. Recommended before starting treatment, when progressing on current therapy, or to confirm that the proposed protocol is correct for that tumor type and stage.
Key benefits:
- Independent review with no obligation to the prior diagnosis
- Analysis of molecular profile and markers if not yet performed
- Evaluation of available treatment alternatives
- In coordination with your treating physician — not against them
“The right treatment isn’t decided by the name of the cancer — it’s decided by the tumor’s biology, its stage, molecular markers, and each person’s situation. That’s what we review in the first consultation.”Dr. Giovanni Reynoso
First consultation available this week
Patients I see frequently.
My practice focuses on solid tumors in adults, with an emphasis on molecular diagnosis, systemic treatment, and second opinions for complex cases or prior failed treatment.
Breast cancer
Lung cancer
Colon and rectal cancer
Prostate cancer
Gastric cancer
Head and neck tumors
Advanced melanoma
Metastatic cancer
Failed prior treatment
Oncology second opinion
Post-treatment surveillance
Patients from Central America
Backed by
Internationally Recognized Organizations
Dr. Reynoso belongs to the world’s most influential oncology societies, ensuring continuous updates on the most demanding clinical protocols and guidelines available for every type of solid tumor.
International Organizations
American Society of Clinical Oncology
Active member of the world’s most influential clinical oncology society, with access to treatment guidelines, up-to-date protocols, and the most relevant oncology research globally.
European Society for Medical Oncology
Member of Europe’s leading oncology society, a global reference for clinical practice guidelines in solid tumors and precision oncology.
Latin American Organizations
Asociación de Investigación Clínica de Guatemala
Active member committed to medical research and the advancement of oncology in Guatemala.
National Organizations
Guatemalan College of Physicians and Surgeons
License #14622 — Committed to medical ethics and excellence in Guatemala.
Guatemalan Association of Oncology
Active member of Guatemala’s leading oncology association.
Specialized oncology care in
Guatemala City
Dr. Reynoso practices at Bonanova Health, a private hospital specializing in cancer, located in Edificio Spazio, Zona 15, Guatemala City — with full institutional support for comprehensive oncologic diagnosis and treatment.
Bonanova Health
Edificio Spazio, 15 avenida y 5 calle 5-50, Vista Hermosa III, Zona 15. Nivel 10, Oficina 10-01
Landmarks
Ideal for patients diagnosed with breast, lung, colon, prostate, gastric, head and neck, or skin cancer seeking specialized oncology care in Guatemala City.
Coverage Areas
Features
Hours & Information
Monday to Tuesday from 4:00 PM to 6:00 PM Thursday from 3:00 PM to 5:00 PM
1-2 hours for first consultation
Consultation Q600
By appointment only
Common questions, clear answers
Still have questions? Let’s talk directly on WhatsApp for personalized answers.